Home > Boards > US Listed > Biotechs > Cytori Therapeutics, Inc. (CYTX)

NEWS -- Cytori Reports Fourth Quarter and Full

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Paulness Member Profile
 
Followed By 70
Posts 10,434
Boards Moderated 0
Alias Born 11/02/03
160x600 placeholder
Paulness   Monday, 04/01/19 09:06:27 AM
Re: None
Post # of 2717 
NEWS -- Cytori Reports Fourth Quarter and Full Year 2018 Business and Financial Results
  • Strategic focus on building a leading oncology company / Lorem Vascular cell therapy transaction yields $4MM
  • Letter of intent for ATI-0918 filed with EMEA
SAN DIEGO, April 01, 2019 (GLOBE NEWSWIRE) -- Cytori Therapeutics (CYTX) (“Cytori” or the “Company”) today announced its fourth quarter and year-end 2018 financial results and provided updates on corporate activities. Also announced was a transaction to divest certain cell therapy assets to Lorem Vascular of Melbourne, Australia yielding $4MM in non-dilutive funding to the Company.

Fourth quarter 2018 net loss was $2.2 million, or $0.16 per share. Operating cash burn for the fourth quarter of 2018 was approximately $2.5 million. Cytori ended the year with approximately $5.3 million of cash and cash equivalents.

The Full Press Release can be found here:

https://finance.yahoo.com/news/cytori-reports-fourth-quarter-full-120500623.html

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences